PKI-179: an Orally Efficacious Dual Phosphatidylinositol-3-kinase (pi3k)/mammalian Target of Rapamycin (mtor) Inhibitor.

Aranapakam M. Venkatesan,Zecheng Chen,Osvaldo Dos Santos,Christoph Dehnhardt,Efren Delos Santos,Semiramis Ayral-Kaloustian,Robert Mallon,Irwin Hollander,Larry Feldberg,Judy Lucas,Ker Yu,Inder Chaudhary,Tarek S. Mansour
DOI: https://doi.org/10.1016/j.bmcl.2010.07.104
IF: 2.94
2010-01-01
Bioorganic & Medicinal Chemistry Letters
Abstract:A series of mono-morpholino 1,3,5-triazine derivatives (8a–8q) bearing a 3-oxa-8-azabicyclo[3.2.1]octane were prepared and evaluated for PI3-kinase/mTOR activity. Replacement of one of the bis-morpholines in lead compound 1 (PKI-587) with 3-oxa-8-azabicyclo[3.2.1]octane and reduction of the molecular weight yielded 8m (PKI-179), an orally efficacious dual PI3-kinase/mTOR inhibitor. The in vitro activity, in vivo efficacy, and PK properties of 8m are discussed.
What problem does this paper attempt to address?